2229 related articles for article (PubMed ID: 28925994)
1. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Neelapu SS; Tummala S; Kebriaei P; Wierda W; Gutierrez C; Locke FL; Komanduri KV; Lin Y; Jain N; Daver N; Westin J; Gulbis AM; Loghin ME; de Groot JF; Adkins S; Davis SE; Rezvani K; Hwu P; Shpall EJ
Nat Rev Clin Oncol; 2018 Jan; 15(1):47-62. PubMed ID: 28925994
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
Kotch C; Barrett D; Teachey DT
Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
[No Abstract] [Full Text] [Related]
3. Toxicities of CD19 CAR-T cell immunotherapy.
Hirayama AV; Turtle CJ
Am J Hematol; 2019 May; 94(S1):S42-S49. PubMed ID: 30784102
[TBL] [Abstract][Full Text] [Related]
4. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Li P; Liu Y; Liang Y; Bo J; Gao S; Hu Y; Hu Y; Huang H; Huang X; Jing H; Ke X; Li J; Li Y; Liu Q; Lu P; Mei H; Niu T; Song Y; Song Y; Su L; Tu S; Wang J; Wu D; Wang Z; Xu K; Ying Z; Yang Q; Zhang Y; Shi F; Zhang B; Zhang H; Zhang X; Zhao M; Zhao W; Zhao X; Huang L; Zhu J; Qian W; Han W; Liang A
Cancer Biol Med; 2023 Mar; 20(2):129-46. PubMed ID: 36861439
[TBL] [Abstract][Full Text] [Related]
5. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
7. Management of cytokine release syndrome related to CAR-T cell therapy.
Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy with CAR-T cells - behold the future.
Graham C; Hewitson R; Pagliuca A; Benjamin R
Clin Med (Lond); 2018 Aug; 18(4):324-328. PubMed ID: 30072559
[TBL] [Abstract][Full Text] [Related]
9. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.
Porter D; Frey N; Wood PA; Weng Y; Grupp SA
J Hematol Oncol; 2018 Mar; 11(1):35. PubMed ID: 29499750
[TBL] [Abstract][Full Text] [Related]
10. Cellular therapy: Immune-related complications.
Oved JH; Barrett DM; Teachey DT
Immunol Rev; 2019 Jul; 290(1):114-126. PubMed ID: 31355491
[TBL] [Abstract][Full Text] [Related]
11. The biological basis and clinical symptoms of CAR-T therapy-associated toxicites.
Titov A; Petukhov A; Staliarova A; Motorin D; Bulatov E; Shuvalov O; Soond SM; Piacentini M; Melino G; Zaritskey A; Barlev NA
Cell Death Dis; 2018 Sep; 9(9):897. PubMed ID: 30181581
[TBL] [Abstract][Full Text] [Related]
12. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
Sterner RC; Sterner RM
Front Immunol; 2022; 13():879608. PubMed ID: 36081506
[TBL] [Abstract][Full Text] [Related]
13. Cytokine release syndrome: grading, modeling, and new therapy.
Liu D; Zhao J
J Hematol Oncol; 2018 Sep; 11(1):121. PubMed ID: 30249264
[TBL] [Abstract][Full Text] [Related]
14. Toxicities following CAR-T therapy for hematological malignancies.
Hernani R; Benzaquén A; Solano C
Cancer Treat Rev; 2022 Dec; 111():102479. PubMed ID: 36308910
[TBL] [Abstract][Full Text] [Related]
15. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.
Hines MR; Knight TE; McNerney KO; Leick MB; Jain T; Ahmed S; Frigault MJ; Hill JA; Jain MD; Johnson WT; Lin Y; Mahadeo KM; Maron GM; Marsh RA; Neelapu SS; Nikiforow S; Ombrello AK; Shah NN; Talleur AC; Turicek D; Vatsayan A; Wong SW; Maus MV; Komanduri KV; Berliner N; Henter JI; Perales MA; Frey NV; Teachey DT; Frank MJ; Shah NN
Transplant Cell Ther; 2023 Jul; 29(7):438.e1-438.e16. PubMed ID: 36906275
[TBL] [Abstract][Full Text] [Related]
16. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Lee DW; Santomasso BD; Locke FL; Ghobadi A; Turtle CJ; Brudno JN; Maus MV; Park JH; Mead E; Pavletic S; Go WY; Eldjerou L; Gardner RA; Frey N; Curran KJ; Peggs K; Pasquini M; DiPersio JF; van den Brink MRM; Komanduri KV; Grupp SA; Neelapu SS
Biol Blood Marrow Transplant; 2019 Apr; 25(4):625-638. PubMed ID: 30592986
[TBL] [Abstract][Full Text] [Related]
17. Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers.
Gupta R; Roach C; Hryniewicki AT; Vilke GM; Shatsky RA; Coyne CJ
J Emerg Med; 2020 Jul; 59(1):61-74. PubMed ID: 32473867
[TBL] [Abstract][Full Text] [Related]
18. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
Freyer CW; Porter DL
J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
[TBL] [Abstract][Full Text] [Related]
19. INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities.
McNerney KO; Hsieh EM; Shalabi H; Epperly R; Wolters PL; Hill JA; Gardner R; Talleur AC; Shah NN; Rossoff J
Transplant Cell Ther; 2024 Jan; 30(1):38-55. PubMed ID: 37821079
[TBL] [Abstract][Full Text] [Related]
20. Management of CAR T-cell Related Toxicities: What did the Learning Curve Teach us so Far?
Murthy HS; Yassine F; Iqbal M; Alotaibi S; Moustafa MA; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):100-111. PubMed ID: 36395496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
